Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,757 results for ""OMALIZUMAB""

Your Filters

Subject : asthma Filter by : Subject Phrase
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Chest CT assess the impact of omalizumab treatment on airway remodeling in refractory asthma.

  • Authors : Shi H; Department of Respiratory and Critical Care Medicine, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China; Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/pharmacology ; Asthma*/Asthma*/Asthma*/drug therapy

  • Source: Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2024 Dec; Vol. 87, pp. 102329. Date of Electronic Publication: 2024 Oct 03.Publisher: Academic Press Country of Publication: England NLM ID: 9715279 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study.

  • Authors : Pianigiani T; Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.; Luzzi S

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Asthma*/Asthma*/Asthma*/metabolism ; Biomarkers*/Biomarkers*/Biomarkers*/analysis

  • Source: The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.

  • Authors : Basagaña M; Allergy Section, Severe Asthma Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.; Martínez-Rivera C

Subjects: Anti-Asthmatic Agents*/Anti-Asthmatic Agents*/Anti-Asthmatic Agents*/therapeutic use ; Anti-Asthmatic Agents*/Anti-Asthmatic Agents*/Anti-Asthmatic Agents*/adverse effects ; Asthma*/Asthma*/Asthma*/drug therapy

  • Source: Annals of medicine [Ann Med] 2024 Dec; Vol. 56 (1), pp. 2317356. Date of Electronic Publication: 2024 Feb 16.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study.

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Dec; Vol. 154 (6), pp. 1500-1510. Date of Electronic Publication: 2024 Aug 24.Publisher: Mosby Country of Publication: United States NLM ID: 1275002 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6825

Record details

Read More Add to Saved list
×
Academic Journal

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.

  • Authors : Zhu R; Genentech, Inc., South San Francisco, California, USA.; Schoemaker R

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Omalizumab*/Omalizumab*/Omalizumab*/pharmacokinetics ; Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use

  • Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Dec; Vol. 90 (12), pp. 3190-3200. Date of Electronic Publication: 2024 Aug 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma.

  • Authors : Desai M; Division of Allergy & Immunology, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA. Electronic address: .; Haines A

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Asthma*/Asthma*/Asthma*/diagnosis ; Biological Products*/Biological Products*/Biological Products*/therapeutic use

  • Source: Immunology and allergy clinics of North America [Immunol Allergy Clin North Am] 2024 Nov; Vol. 44 (4), pp. 737-750.Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8805635 Publication Model: Print Cited Medium: Internet ISSN: 1557-8607

Record details

Read More Add to Saved list
×
Academic Journal

Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics.

  • Authors : Nopsopon T; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Brown A

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Biological Products*/Biological Products*/Biological Products*/therapeutic use ; Anti-Asthmatic Agents*/Anti-Asthmatic Agents*/Anti-Asthmatic Agents*/therapeutic use

  • Source: Respiratory medicine [Respir Med] 2024 Nov-Dec; Vol. 234, pp. 107802. Date of Electronic Publication: 2024 Sep 10.Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of subcutaneous immunotherapy combined with omalizumab in children with dust mite-induced asthma.

  • Authors : Long C; Department of Pediatrics (III), Linyi People's Hospital, Linyi, Shandong, China.; Sun C

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Omalizumab*/Omalizumab*/Omalizumab*/adverse effects

  • Source: The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab.

  • Authors : Cilli A; Department of Respiratory Disease, Akdeniz University, Antalya, Türkiye.; Uzer F

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Asthma*/Asthma*/Asthma*/drug therapy

  • Source: The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.

  • Authors : Deshmukh AD; Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Georgia State University College of Law, Atlanta, Georgia, USA.

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Asthma*/Asthma*/Asthma*/drug therapy

  • Source: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 Oct; Vol. 33 (10), pp. e70009.Publisher: Wiley Country of Publication: England NLM ID: 9208369 Publication Model: Print Cited Medium: Internet ISSN: 1099-1557 (Electronic)

Record details

Read More Add to Saved list
×
  • 1-10 of  1,757 results for ""OMALIZUMAB""